荃信生物-B(02509.HK)預計3月20日上市 引入華東醫藥等作為基石
格隆匯3月12日丨荃信生物-B(02509.HK)發佈公吿，公司擬全球發售股份1204.64萬股，中國香港發售股份120.48萬股，國際發售股份1084.16萬股；2024年3月12日至3月15日招股，預期定價日為3月18日；發售價將為每股發售股份19.80-20.20港元，每手買賣單位200股；中金公司為獨家保薦人；預期股份將於2024年3月20日於聯交所主板掛牌上市。
創辦於2015年，公司是一家完全專注於針對自身免疫及過敏性疾病生物療法的臨牀階段生物科技公司。公司擁有兩個核心產品QX002N及QX005N，均為自行開發。 QX002N是一種IL-17A抑制劑，公司已在中國就治療強直性脊柱炎(AS)開展III期臨牀試驗。QX005N是一種阻斷IL-4Rα的單克隆抗體(mAb)，公司已在中國啟動用於特應性皮炎(AD)、結節性癢疹(PN)及慢性鼻竇炎合併鼻息肉(CRSwNP)的II期臨牀試驗。截至最後實際可行日期，除核心產品外，公司還有其他七種管線候選藥物，其中四種處於臨牀階段。公司的產品管線涵蓋了自身免疫和過敏性疾病的四個主要領域，即皮膚、風濕、呼吸道及消化道疾病。
公司已訂立基石投資協議，據此，基石投資者已同意，在若干條件規限下按發售價認購相關發售股份數目，而相關發售股份可以總額2500萬美元(或約1.957億港元)購買。假設發售價為20.00港元(即本招股章程所載指示性發售價範圍的中位數)，基石投資者將認購的發售股份總數將為978.52萬股。基石投資者包括健鑫醫藥(由公司現有股東泰州健鑫全資擁有)、華東投資(華東醫藥(000963.SZ)的全資附屬公司)、以及蜂投資本(由鄺建鴻全資擁有)。
假設發售價為每股發售股份20.00港元，公司估計將獲得所得款項淨額約1.635億港元。公司計劃將全球發售所得款項淨額約30.1%分配至公司核心產品QX002N的開發及註冊；約54.6%將分配至公司其他核心產品QX005N的開發及註冊；約8.7%將分配至QX004N的開發及註冊；約1.9%將分配至QX006N的臨牀試驗(包括試驗地點、CRO 及受試者入組的成本)、QX006N準備註冊文件以及CMC成本；及約4.7%將分配至公司若干其他資產(包括QX007N、QX010N 及QX013N)的研發和藥物發現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
